polatuzumab vedotin   Click here for help

GtoPdb Ligand ID: 8404

Synonyms: ACD79B-VCMMAE | polatuzumab vedotin-piiq | Polivy® | RG-7596 | RG7596 | RO5541077-000
Approved drug Immunopharmacology Ligand
polatuzumab vedotin is an approved drug (FDA (2019), EMA (2020))
Compound class: Antibody
Comment: Polatuzumab vedotin is an antibody drug conjugate containing an anti-CD79b monoclonal antibody linked to the toxin monomethyl auristatin E (MMAE, aka vedotin; PubChem CID 11542188).
Peptide sequence information for this antibody is available from its IMGT/mAb-DB record. Peptide sequence matches identify US8088378 as the claiming patent [1].
No information available.
Summary of Clinical Use Click here for help
The EMA granted polatuzumab vedotin orphan designation for the treatment of aggressive lymphoma (relapsed/refractory diffuse large B-cell lymphoma; DLBCL) in April 2018. In June 2019, the FDA granted accelerated approval for the use of polatuzumab vedotin (Polivy®) [2] as a treatment for DLBCL that has progressed following treatment with at least two previous therapies. Polivy is to be used in combination with bendamustine and a rituximab product in these patients. This accelerated approval was granted based on results from NCT02257567 [2]. Click here to link to ClinicalTrials.gov's full list of polatuzumab vedotin trials. Full EMA marketing authorisation was granted in January 2020.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02257567 A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma Phase 1/Phase 2 Interventional Hoffmann-La Roche